Vident Advisory LLC Purchases 22,261 Shares of Illumina, Inc. $ILMN

Key Points

• Vident Advisory LLC increased its holdings in Illumina, Inc. by 22.4% in Q1, now owning 121,609 shares valued at approximately $9.6 million.
• Various institutional investors, including Rakuten Securities Inc. and PFS Partners LLC, have also significantly increased their positions in Illumina this quarter.
• Illumina reported earnings of $1.19 EPS for the latest quarter, which exceeded analysts' expectations, although revenue saw a year-over-year decline of 4.8%.

Vident Advisory LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 121,609 shares of the life sciences company's stock after buying an additional 22,261 shares during the period. Vident Advisory LLC owned approximately 0.08% of Illumina worth $9,648,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Fourth Dimension Wealth LLC bought a new stake in Illumina in the fourth quarter valued at approximately $40,000. Rakuten Securities Inc. grew its position in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. bought a new position in Illumina in the first quarter valued at $33,000. PFS Partners LLC grew its position in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its position in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ILMN shares. Guggenheim decreased their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research report on Friday, July 11th. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a report on Tuesday. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their target price for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Finally, Robert W. Baird lifted their price target on shares of Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of "Hold" and an average price target of $123.06.

Illumina Trading Down 0.6%

Shares of NASDAQ ILMN traded down $0.55 during midday trading on Thursday, reaching $95.53. The stock had a trading volume of 534,926 shares, compared to its average volume of 2,283,924. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company's 50 day moving average price is $99.47 and its 200 day moving average price is $88.58. The firm has a market cap of $14.68 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 2.25 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company earned $0.36 EPS. Illumina's quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.